The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Research Methods · Statistics · continued

Regression to the mean in progress reports posts 31–35

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

NK
n.kuuselaTL2 Moderator11 Jul 2025#31
a.molnar, post #2: Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had been repeating something I had not checked carefully enough. Go to post

I read post #29 twice before replying, because I had assumed the opposite.

Relative risk and odds ratios: both compare the rate in one group to the rate in another. Relative risk is easier to understand. Odds ratios are standard in many analyses but can be misinterpreted.

2 likes in reply to #2 13mo
PW
PharmNotes_WhitfieldTL413 Jul 2025#32
SC
s.cabreraTL2 Moderator16 Jul 2025#33

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

27 likes 12mo
DO
dr_okonkwoTL4 Moderator18 Jul 2025#34

P-values and significance: p<0.05 means the data would be surprising if the null hypothesis were true, not that the null hypothesis is false. A non-significant p-value does not mean "no effect".

13 likes 12mo
EH
e.halonenTL2 Moderator20 Jul 2025 · edited#35

Effect sizes: the magnitude of a difference, not just whether it is statistically significant. A difference that is significant (p<0.05) might be too small to matter. A large effect might not be significant if sample size is small.

4 likes 12mo

Suggested topics

TopicParticipantsRepliesViewsActivity
About the Statistics category
Effect sizes, intervals, multiplicity, and the difference between absent and undetected. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
SLJMBVCAV+4 8 2.3k 7mo
Second pass at: Regression to the mean in progress reports
Second pass at: Regression to the mean in progress reports Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with STEP 4 ( JAMA ,…
SGCKIAMDM+71 75 4k 17mo
Sample size intuition for a personal experiment
On the subject in the title: Sample size intuition for a personal experiment Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is…
RKHECAHTT 4 62k 18mo
Second pass at: Multiplicity when you track fifteen variables
Posting this under the heading it deserves: Second pass at: Multiplicity when you track fifteen variables Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…
KFFFRM 2 12k 18mo
Absence of evidence and evidence of absence
Absence of evidence and evidence of absence Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read it before…
KRFDRNRMHF+16 20 3.9k 5mo

Related topics — sharing the tags number needed to treat, heterogeneity, confounding

TopicParticipantsRepliesViewsActivity
Pooling trials with different estimands
On the subject in the title: Pooling trials with different estimands Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding the…
RCFCTSRMME+120 132 2.3k 1d
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold?
Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Session topic: STEP 2 ( Lancet , 2021). Please read…
DNSLITNCAS+43 47 5.5k just now
Immortal time bias in a claims-database study — one year on
Posting this under the heading it deserves: Immortal time bias in a claims-database study — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SURMOUNT-1 (…
VMDMMGRPT+41 46 3.7k 22h
Coming back to: Half-life, steady state, and accumulation worked through
On the subject in the title: Half-life, steady state, and accumulation worked through Working notes rather than a conclusion. Working through the identity arithmetic and I would like it checked. semaglutide…
CRHKASMISC+14 18 15k 3mo
Gauge and length selection for subcutaneous injection
Gauge and length selection for subcutaneous injection Writing it up because I had to work it out twice and would rather nobody else did. Practical question with the units stated, because I have seen how…
NVARNSOBHM+50 55 1.3k 8mo